,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,357,2,1,,11111261,3637,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
1,357,2,1,,11111262,3637,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
2,410,1,5,,11111261,3637,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
3,410,1,5,,11111262,3637,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
4,411,2,1,,11111261,3637,Active,160794.0,,12.5893,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
5,411,2,1,,11111262,3637,Active,160794.0,,3.9811,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
6,444,1,1,,11111261,3637,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
7,444,1,1,,11111262,3637,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
8,445,3,1,,11111261,3637,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
9,445,3,1,,11111262,3637,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
10,446,1,1,,11111261,3637,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
11,446,1,1,,11111262,3637,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
12,447,1,1,,11111261,3637,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
13,447,1,1,,11111262,3637,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
14,448,1,2,,11111261,3637,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
15,448,1,2,,11111262,3637,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
16,450,1,2,,11111261,3637,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
17,450,1,2,,11111262,3637,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
18,451,1,2,,11111261,3637,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
19,451,1,2,,11111262,3637,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
20,526,1,1,,11111261,3637,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
21,526,1,1,,11111262,3637,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
22,530,1,1,,11111261,3637,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
23,530,1,1,,11111262,3637,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
24,584,1,3,,11111261,3637,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
25,584,1,3,,11111262,3637,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
26,585,1,4,,11111261,3637,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
27,585,1,4,,11111262,3637,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
28,587,1,5,,11111261,3637,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
29,587,1,5,,11111262,3637,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
30,588,1,4,,11111261,3637,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
31,588,1,4,,11111262,3637,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
32,589,1,3,,11111261,3637,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
33,589,1,3,,11111262,3637,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
34,590,1,3,,11111261,3637,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
35,590,1,3,,11111262,3637,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
36,591,1,4,,11111261,3637,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
37,591,1,4,,11111262,3637,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
38,592,1,6,,11111261,3637,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
39,592,1,6,,11111262,3637,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
40,593,1,4,,11111261,3637,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
41,593,1,4,,11111262,3637,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
42,594,1,4,,11111261,3637,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
43,594,1,4,,11111262,3637,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
44,595,1,3,,11111261,3637,Inconclusive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
45,595,1,3,,11111262,3637,Active,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
46,596,1,2,,11111261,3637,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
47,596,1,2,,11111262,3637,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
48,597,1,3,,11111261,3637,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
49,597,1,3,,11111262,3637,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
50,603,1,2,,11111261,3637,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
51,603,1,2,,11111262,3637,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
52,605,1,2,,11111261,3637,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
53,605,1,2,,11111262,3637,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
54,607,1,3,,11111261,3637,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
55,607,1,3,,11111262,3637,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
56,662,1,1,,11111261,3637,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
57,662,1,1,,11111262,3637,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
58,875,1,2,,11111261,3637,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
59,875,1,2,,11111262,3637,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
60,879,1,2,,11111261,3637,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
61,879,1,2,,11111261,3637,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
62,880,2,1,,11111262,3637,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
63,880,2,1,,11111262,3637,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
64,881,2,2,,11111261,3637,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
65,881,2,2,,11111262,3637,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
66,883,1,3,,11111261,3637,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
67,883,1,3,,11111262,3637,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
68,884,1,2,,11111261,3637,Inconclusive,13435386.0,1576.0,12.5893,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
69,884,1,2,,11111262,3637,Inconclusive,13435386.0,1576.0,3.9811,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
70,885,1,2,,11111261,3637,Inactive,13435386.0,1576.0,12.5893,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
71,885,1,2,,11111262,3637,Inactive,13435386.0,1576.0,3.9811,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
72,886,1,2,,11111261,3637,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
73,886,1,2,,11111261,3637,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
74,886,1,2,,11111262,3637,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
75,886,1,2,,11111262,3637,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
76,887,1,2,,11111261,3637,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
77,887,1,2,,11111262,3637,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
78,889,1,3,,11111261,3637,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
79,889,1,3,,11111262,3637,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
80,891,1,2,,11111261,3637,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
81,891,1,2,,11111262,3637,Inconclusive,40805836.0,1565.0,12.5893,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
82,892,1,2,,11111261,3637,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
83,892,1,2,,11111262,3637,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
84,893,1,2,,11111261,3637,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
85,893,1,2,,11111261,3637,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
86,893,1,2,,11111262,3637,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
87,893,1,2,,11111262,3637,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
88,894,2,1,,11111262,3637,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
89,895,1,2,,11111261,3637,Inactive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
90,899,1,2,,11111261,3637,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
91,899,1,2,,11111262,3637,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
92,900,1,3,,11111261,3637,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
93,900,1,3,,11111262,3637,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
94,901,1,2,,11111261,3637,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
95,901,1,2,,11111262,3637,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
96,902,1,2,,11111261,3637,Inconclusive,120407068.0,7157.0,1.5849,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
97,902,1,2,,11111262,3637,Inconclusive,120407068.0,7157.0,2.5119,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
98,912,1,2,,11111261,3637,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
99,912,1,2,,11111262,3637,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
100,914,1,3,,11111261,3637,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
101,914,1,3,,11111262,3637,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
102,915,1,3,,11111261,3637,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
103,915,1,3,,11111262,3637,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
104,917,1,3,,11111261,3637,Active,120660324.0,7066.0,0.0398,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
105,918,1,3,,11111261,3637,Inconclusive,120660324.0,7066.0,0.0398,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
106,923,1,2,,11111261,3637,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
107,923,1,2,,11111262,3637,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
108,924,1,2,,11111261,3637,Inconclusive,120407068.0,7157.0,3.9811,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
109,924,1,2,,11111262,3637,Inconclusive,120407068.0,7157.0,2.5119,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
110,925,1,2,,11111261,3637,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
111,925,1,2,,11111262,3637,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
112,926,1,2,,11111261,3637,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
113,926,1,2,,11111262,3637,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
114,927,1,3,,11111261,3637,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
115,927,1,3,,11111262,3637,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
116,928,1,2,,11111261,3637,Inactive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
117,938,1,2,,11111261,3637,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
118,938,1,2,,11111262,3637,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
119,943,1,2,,11111261,3637,Inconclusive,18249941.0,25229.0,0.0282,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
120,944,1,2,,11111261,3637,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
121,945,1,4,,11111261,3637,Inconclusive,290753097.0,,1.9953,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
122,954,1,2,,11111261,3637,Inactive,33286420.0,5315.0,7.9433,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
123,957,1,2,,11111261,3637,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
124,958,1,2,,11111261,3637,Active,33286420.0,5315.0,7.9433,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
125,959,1,4,,11111261,3637,Inactive,290753097.0,,1.9953,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
126,992,1,3,,11111261,3637,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
127,995,1,2,,11111261,3637,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
128,995,1,2,,11111262,3637,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
129,997,1,2,,11111261,3637,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
130,998,1,2,,11111261,3637,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
131,1030,2,1,,11111262,3637,Inconclusive,30582681.0,216.0,5.0119,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
132,1195,1,2,,48416088,3637,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
133,1379,1,2,,11111262,3637,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
134,1452,1,1,,11111261,3637,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
135,1452,1,1,,11111262,3637,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
136,1454,1,1,,11111262,3637,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
137,1457,1,1,,11111262,3637,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
138,1458,1,1,,11111262,3637,Active,10937869.0,6607.0,3.9811,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
139,1467,1,3,,11111262,3637,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
140,1469,1,1,,11111262,3637,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
141,1471,2,1,,11111261,3637,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
142,1471,2,1,,11111262,3637,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
143,1476,2,1,,11111262,3637,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
144,1477,1,1,,11111262,3637,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
145,1478,2,1,,11111262,3637,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
146,1479,1,2,,11111262,3637,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
147,1487,1,1,,11111262,3637,Inconclusive,27436948.0,4000.0,3.1623,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
148,1490,2,1,,11111262,3637,Active,10954339.0,,5.0119,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
149,1519,1,3,,11111262,3637,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
150,1688,1,1,,11111262,3637,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
151,1766,1,1,,11111262,3637,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
152,1766,1,1,,11111262,3637,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
153,1768,1,1,,11111262,3637,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
154,1768,1,1,,11111262,3637,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
155,1851,1,2,,11111261,3637,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
156,1851,1,2,,11111262,3637,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
157,1851,1,2,1.0,11111261,3637,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
158,1851,1,2,1.0,11111262,3637,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
159,1851,1,2,2.0,11111261,3637,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
160,1851,1,2,2.0,11111262,3637,Inconclusive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
161,1851,1,2,3.0,11111261,3637,Inconclusive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
162,1851,1,2,3.0,11111262,3637,Inconclusive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
163,1851,1,2,4.0,11111261,3637,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
164,1851,1,2,4.0,11111262,3637,Active,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
165,1851,1,2,5.0,11111261,3637,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
166,1851,1,2,5.0,11111262,3637,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
167,1865,1,1,,11111262,3637,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
168,1948,1,1,,11111262,3637,Inactive,,,12.5893,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
169,2101,1,1,,11111262,3637,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
170,2107,1,1,,11111262,3637,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
171,2112,1,1,,11111262,3637,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
172,2147,1,1,,11111262,3637,Inconclusive,221046486.0,,12.5893,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
173,2240,1,1,,85789545,3637,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
174,2241,1,1,,85789545,3637,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
175,2275,1,1,,85789545,3637,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
176,2313,1,1,,85789545,3637,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
177,2322,1,1,,85789545,3637,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
178,2330,1,1,,85789545,3637,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
179,2451,1,2,,11111262,3637,Active,122920737.0,,12.5594,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
180,2472,1,2,,11111262,3637,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
181,2528,1,2,,11111262,3637,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
182,2546,1,1,,11111262,3637,Inconclusive,188536040.0,19885.0,14.1254,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
183,2549,1,1,,11111262,3637,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
184,2551,1,1,,11111262,3637,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
185,2660,1,1,,90341825,3637,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
186,2662,2,1,,11111262,3637,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
187,2666,1,1,,90341825,3637,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
188,2667,1,1,,90341825,3637,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
189,2668,1,1,,90341825,3637,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
190,2701,1,1,,11111262,3637,Inconclusive,10954339.0,,28.3112,Potency,Confirmation qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
191,2707,1,2,,11111262,3637,Active,10954339.0,,74.5,Potency,Gel-Based Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
192,13770,3,3,,103171825,3637,Unspecified,,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Other,7452697.0,
193,13782,3,3,,103171825,3637,Unspecified,,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Other,7452697.0,
194,13788,3,3,,103171825,3637,Unspecified,,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Other,7452697.0,
195,13806,3,3,,103171825,3637,Unspecified,,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),Other,7452697.0,
196,13957,3,3,,103171825,3637,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Other,7452697.0,
197,13969,3,3,,103171825,3637,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Other,7452697.0,
198,13992,3,3,,103171825,3637,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),Other,7452697.0,
199,16562,3,3,,103171825,3637,Unspecified,,,,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Other,7452697.0,
200,16565,3,3,,103171825,3637,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Other,7452697.0,
201,16577,3,3,,103171825,3637,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Other,7452697.0,
202,16583,3,3,,103171825,3637,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Other,7452697.0,
203,16602,3,3,,103171825,3637,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),Other,7452697.0,
204,27167,3,4,,103171825,3637,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
205,28681,3,4,,103171825,3637,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
206,29359,3,3,,103171825,3637,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
207,29811,4,3,,103171825,3637,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
208,57653,7,1,,103171825,3637,Unspecified,,,,,Tested for increase in iliac blood flow was measured in anesthetized dogs before timolol administered intra arterially at dose 1600 mg/kg,Other,6102151.0,
209,57655,7,1,,103171825,3637,Unspecified,,,,,Tested for increase in iliac blood flow was measured in anesthetized dogs before timolol administered intra arterially at dose 3200 mg/kg,Other,6102151.0,
210,57656,7,1,,103171825,3637,Unspecified,,,,,Tested for increase in iliac blood flow was measured in anesthetized dogs before timolol administered intra arterially at dose 400 mg/kg,Other,6102151.0,
211,58974,6,1,,103171825,3637,Unspecified,,,,,Effect of compound (given intravenously) on heart rate in conscious renal hypertensive dogs at 0 h,Other,6747991.0,
212,58975,6,1,,103171825,3637,Unspecified,,,,,Effect of compound (given intravenously) on heart rate in conscious renal hypertensive dogs at 10 h,Other,6747991.0,
213,58976,6,1,,103171825,3637,Unspecified,,,,,Effect of compound (given intravenously) on heart rate in conscious renal hypertensive dogs at 12 h,Other,6747991.0,
214,58977,6,1,,103171825,3637,Unspecified,,,,,Effect of compound (given intravenously) on heart rate in conscious renal hypertensive dogs at 20 h,Other,6747991.0,
215,58978,6,1,,103171825,3637,Unspecified,,,,,Effect of compound (given intravenously) on heart rate in conscious renal hypertensive dogs at 4 h,Other,6747991.0,
216,58979,6,1,,103171825,3637,Unspecified,,,,,Effect of compound (given intravenously) on heart rate in conscious renal hypertensive dogs at 6 h,Other,6747991.0,
217,58981,6,1,,103171825,3637,Unspecified,,,,,Effect of compound (given intravenously) on heart rate in conscious renal hypertensive dogs at t8 h,Other,6747991.0,
218,60593,3,4,,103171825,3637,Unspecified,,,,,Effect of compound (given intravenously) on systolic blood pressure in conscious renal hypertensive dogs at 0 h,Other,6747991.0,
219,60594,3,4,,103171825,3637,Unspecified,,,,,Effect of compound (given intravenously) on systolic blood pressure in conscious renal hypertensive dogs at 10 h,Other,6747991.0,
220,60595,3,4,,103171825,3637,Unspecified,,,,,Effect of compound (given intravenously) on systolic blood pressure in conscious renal hypertensive dogs at 12 h,Other,6747991.0,
221,60596,3,4,,103171825,3637,Unspecified,,,,,Effect of compound (given intravenously) on systolic blood pressure in conscious renal hypertensive dogs at 20 h,Other,6747991.0,
222,60597,3,4,,103171825,3637,Unspecified,,,,,Effect of compound (given intravenously) on systolic blood pressure in conscious renal hypertensive dogs at 4 h,Other,6747991.0,
223,60598,3,4,,103171825,3637,Unspecified,,,,,Effect of compound (given intravenously) on systolic blood pressure in conscious renal hypertensive dogs at 6 h,Other,6747991.0,
224,60599,3,4,,103171825,3637,Unspecified,,,,,Effect of compound (given intravenously) on systolic blood pressure in conscious renal hypertensive dogs at 8 h,Other,6747991.0,
225,80775,3,4,,103171825,3637,Unspecified,,,,,Inhibition of ADP-induced platelet aggregation in guinea pig whole blood at 5*10e-4 M,Other,1656043.0,
226,80784,3,4,,103171825,3637,Unspecified,,,,,Inhibition of arachidonic acid induced platelet aggregation in guinea pig whole blood at 5*10e-4 M,Other,1656043.0,
227,159523,3,7,,103171825,3637,Unspecified,,,,,Inhibition of canine heart Phosphodiesterase 4 at 100 uM,Other,1656043.0,
228,170448,3,4,,103171825,3637,Unspecified,,,,,"The compound was tested for antihypertensive activity in spontaneously hypertensive rats after peroral administration, at a dose of 4 mg/kg",Other,6102605.0,
229,170691,3,4,,103171825,3637,Unspecified,,,,,Percent change of heart rate in conscious DOCA Hypertensive rat at 1 hour after administration of dose of 10 mL (mg/kg po),Other,6125596.0,
230,170692,3,4,,103171825,3637,Unspecified,,,,,Percent change of heart rate in conscious DOCA Hypertensive rat at 2 hour after administration of dose of 10 mL (mg/kg po),Other,6125596.0,
231,170693,3,4,,103171825,3637,Unspecified,,,,,Percent change of heart rate in conscious DOCA Hypertensive rat at 22 hour after administration of dose of 10 mL (mg/kg po),Other,6125596.0,
232,170694,3,4,,103171825,3637,Unspecified,,,,,Percent change of heart rate in conscious DOCA Hypertensive rat at 3 hour after administration of dose of 10 mL (mg/kg po),Other,6125596.0,
233,170695,3,4,,103171825,3637,Unspecified,,,,,Percent change of heart rate in conscious DOCA Hypertensive rat at 5 hour after administration of dose of 10 mL (mg/kg po),Other,6125596.0,
234,170699,3,4,,103171825,3637,Unspecified,,,,,"Percent change of mean arterial blood pressure in conscious DOCA Hypertensive rat at 1 hour, after administration of dose 10 mL (mg/kg po)",Other,6125596.0,
235,170700,3,4,,103171825,3637,Unspecified,,,,,"Percent change of mean arterial blood pressure in conscious DOCA Hypertensive rat at 2 hour, after administration of dose 10 mL (mg/kg po)",Other,6125596.0,
236,170701,3,4,,103171825,3637,Unspecified,,,,,"Percent change of mean arterial blood pressure in conscious DOCA Hypertensive rat at 22 hour, after administration of dose 10 mL (mg/kg po)",Other,6125596.0,
237,170702,3,4,,103171825,3637,Unspecified,,,,,"Percent change of mean arterial blood pressure in conscious DOCA Hypertensive rat at 3 hour, after administration of dose 10 mL (mg/kg po)",Other,6125596.0,
238,170703,3,4,,103171825,3637,Unspecified,,,,,"Percent change of mean arterial blood pressure in conscious DOCA Hypertensive rat at 5 hour, after administration of dose 10 mL (mg/kg po)",Other,6125596.0,
239,172111,3,4,,103171825,3637,Unspecified,,,,,Antihypertensive activity rating in conscious SHR after 10 hr post dose at 10 mg/kg (po); Range 20-30%,Other,6827558.0,
240,172120,3,3,,103171825,3637,Unspecified,,,,,Antihypertensive activity rating in conscious SHR after 2 h post dose at 10 mg/kg (po),Other,6827558.0,
241,172124,3,4,,103171825,3637,Unspecified,,,,,Antihypertensive activity rating in conscious SHR after 2 hr post dose at 3 mg/kg (po); Range 20-30%,Other,6827558.0,
242,172131,3,3,,103171825,3637,Unspecified,,,,,Antihypertensive activity rating in conscious SHR after 24 h post dose at 10 mg/kg (po); Range 10-20%,Other,6827558.0,
243,172140,3,3,,103171825,3637,Unspecified,,,,,"Blood pressure rating in spontaneously hypertensive rats, 10 hr after peroral administration of 1 mg/kg of compound",Other,7265125.0,
244,172141,3,3,,103171825,3637,Unspecified,,,,,"Blood pressure rating in spontaneously hypertensive rats, 10 hr after peroral administration of 10 mg/kg of compound",Other,7265125.0,
245,172142,3,3,,103171825,3637,Unspecified,,,,,"Blood pressure rating in spontaneously hypertensive rats, 10 hr after peroral administration of 3 mg/kg of compound",Other,7265125.0,
246,172263,3,3,,103171825,3637,Unspecified,,,,,"Blood pressure rating in spontaneously hypertensive rats, 24 hr after peroral administration of 1 mg/kg of compound",Other,7265125.0,
247,172264,3,3,,103171825,3637,Unspecified,,,,,"Blood pressure rating in spontaneously hypertensive rats, 24 hr after peroral administration of 10 mg/kg of compound",Other,7265125.0,
248,172265,3,3,,103171825,3637,Unspecified,,,,,"Blood pressure rating in spontaneously hypertensive rats, 24 hr after peroral administration of 3 mg/kg of compound",Other,7265125.0,
249,172267,3,3,,103171825,3637,Unspecified,,,,,"Blood pressure rating in spontaneously hypertensive rats, 2 hr after peroral administration of 1 mg/kg of compound",Other,7265125.0,
250,172268,3,3,,103171825,3637,Unspecified,,,,,"Blood pressure rating in spontaneously hypertensive rats, 2 hr after peroral administration of 10 mg/kg of compound",Other,7265125.0,
251,172269,3,3,,103171825,3637,Unspecified,,,,,"Blood pressure rating in spontaneously hypertensive rats, 2 hr after peroral administration of 3 mg/kg of compound",Other,7265125.0,
252,173507,4,4,,103171825,3637,Unspecified,,,,,Maximum percent decrease in blood pressure in SHR ( hour post dose in parentheses),Other,6827558.0,
253,173515,3,4,,103171825,3637,Unspecified,,,,,"Maximum percent decrease in heart rate of spontaneously hypertensive rats, 1 hours after peroral administration of 3 mg/kg of compound",Other,7265125.0,
254,173524,3,4,,103171825,3637,Unspecified,,,,,"Maximum percent decrease in heart rate of spontaneously hypertensive rats, 4 hr after peroral administration of 10 mg/kg of compound",Other,7265125.0,
255,174281,3,5,,103171825,3637,Unspecified,,,,,Compound was tested for antihypertensive activity in rat after 1 hr postdose,Other,3712385.0,
256,174282,3,5,,103171825,3637,Unspecified,,,,,Compound was tested for antihypertensive activity in rat after 24 hr postdose,Other,3712385.0,
257,174283,3,5,,103171825,3637,Unspecified,,,,,Compound was tested for antihypertensive activity in rat after 4 hr postdose,Other,3712385.0,
258,174422,3,4,,103171825,3637,Unspecified,,,,,Change in systolic blood pressure after 10 mg/kg oral administration in spontaneous hypertensive rats after 24 hr,Other,7310823.0,
259,174423,3,4,,103171825,3637,Unspecified,,,,,Change in systolic blood pressure after 10 mg/kg oral administration in spontaneous hypertensive rats after 2 hr,Other,7310823.0,
260,174424,3,4,,103171825,3637,Unspecified,,,,,Change in systolic blood pressure after 10 mg/kg oral administration in spontaneous hypertensive rats after 4 hr,Other,7310823.0,
261,174565,3,4,,103171825,3637,Unspecified,,,,,Change in systolic blood pressure after 5 mg/kg oral administration in spontaneous hypertensive rats after 24 hr,Other,7310823.0,
262,174566,3,4,,103171825,3637,Unspecified,,,,,Change in systolic blood pressure after 5 mg/kg oral administration in spontaneous hypertensive rats after 2 hr,Other,7310823.0,
263,174567,3,4,,103171825,3637,Unspecified,,,,,Change in systolic blood pressure after 5 mg/kg oral administration in spontaneous hypertensive rats after 4 hr,Other,7310823.0,
264,174953,4,3,,103171825,3637,Unspecified,,,,,Time taken for the decrease in arterial pressure was measured,Other,7452697.0,
265,176932,7,2,,103171825,3637,Unspecified,,,,,Dose required to produce a 50% increase in blood flow to the autoperfused hindquarters of the anesthetized rat,Other,2892934.0,
266,177366,3,4,,103171825,3637,Unspecified,,,,,Dose required to produce a fall in blood pressure of 40 mmHg in the anesthetized rat,Other,2892934.0,
267,181306,3,4,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in DOCA/saline rat dosed at 2 mg/kg, administered perorally expressed as percent fall in blood pressure after 2 h",Other,6827559.0,
268,181312,5,3,,103171825,3637,Inactive,,,,,"Antihypertensive activity in DOCA/saline rat dosed at 2 mg/kg, administered perorally expressed as percent fall in blood pressure after 6 h; NS is not significant",Other,6827559.0,
269,181967,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 0.03 ug/kg intravenous dosing of angiotensin in pithed rats,Other,3361578.0,
270,181968,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 0.03 ug/kg intravenous dosing of angiotensin in pithed rats,Other,3361579.0,
271,181969,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 0.1 ug/kg intravenous dosing of angiotensin in pithed rats,Other,3361578.0,
272,181970,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 0.1 ug/kg intravenous dosing of angiotensin in pithed rats,Other,3361579.0,
273,181971,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 0.1 ug/kg intravenous dosing of noradrenaline in pithed rats,Other,3361578.0,
274,181972,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 0.1 ug/kg intravenous dosing of noradrenaline in pithed rats,Other,3361579.0,
275,181973,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 0.3 ug/kg intravenous dosing of angiotensin in pithed rats,Other,3361578.0,
276,181974,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 0.3 ug/kg intravenous dosing of angiotensin in pithed rats,Other,3361579.0,
277,181975,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 0.3 ug/kg intravenous dosing of noradrenaline in pithed rats,Other,3361578.0,
278,181976,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 0.3 ug/kg intravenous dosing of noradrenaline in pithed rats,Other,3361579.0,
279,181977,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 1 Htz electrical stimulation in the pithed rats,Other,3361578.0,
280,181978,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 1 Htz electrical stimulation in the pithed rats,Other,3361579.0,
281,181979,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 1.0 ug/kg intravenous dosing of noradrenaline in pithed rats,Other,3361578.0,
282,181980,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 1.0 ug/kg intravenous dosing of noradrenaline in pithed rats,Other,3361579.0,
283,181981,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 3 Htz electrical stimulation in the pithed rats,Other,3361578.0,
284,181982,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 3 Htz electrical stimulation in the pithed rats,Other,3361579.0,
285,181983,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 6 Htz electrical stimulation in the pithed rats,Other,3361578.0,
286,181984,3,4,,103171825,3637,Unspecified,,,,,Increase in diastolic blood pressure for 6 Htz electrical stimulation in the pithed rats,Other,3361579.0,
287,182174,3,3,,103171825,3637,Unspecified,,,,,Compound was tested at 1.5e-3M for inhibition of spontaneous activity in rat isolated portal vein,Other,6631915.0,
288,185886,3,4,,103171825,3637,Unspecified,,,,,Maximum fall in systolic blood pressure at interval from 1 to 6 hours at a dose of 1 mg/kg when administered perorally in rats,Other,6631915.0,
289,185887,3,4,,103171825,3637,Unspecified,,,,,"Maximum fall in systolic blood pressure, intervals from 1 to 6 hours at a dose of 10 mg/kg administered per orally",Other,6631915.0,
290,185889,3,4,,103171825,3637,Unspecified,,,,,Maximum fall in systolic blood pressure at interval from 1 to 6 hours at a dose of 3 mg/kg when administered perorally in rats,Other,6631915.0,
291,186853,3,4,,103171825,3637,Unspecified,,,,,Maximum fall in mean arterial blood pressure was measured in SH rats when compound was administered at 0.5 mg/kg perorally (0-6 hr),Other,7452697.0,
292,186856,3,4,,103171825,3637,Unspecified,,,,,Maximum fall in mean arterial blood pressure was measured in SH rats when compound was administered at 1 mg/kg perorally (0-6 hr),Other,7452697.0,
293,186858,3,4,,103171825,3637,Unspecified,,,,,Maximum fall in mean arterial blood pressure was measured in SH rats when compound was administered at 2 mg/kg perorally,Other,7452697.0,
294,187011,3,3,,103171825,3637,Unspecified,,,,,Tested for maximum fall in mean arterial pressure in Spontaneously hypertensive rats after peroral administration by using 1% methyl cellulose as vehicle at 0.5 mg/kg,Other,6102151.0,
295,187012,3,3,,103171825,3637,Unspecified,,,,,Tested for maximum fall in mean arterial pressure in Spontaneously hypertensive rats after peroral administration by using 1% methyl cellulose as vehicle at 1 mg/kg,Other,6102151.0,
296,187014,3,3,,103171825,3637,Unspecified,,,,,Tested for maximum fall in mean arterial pressure in Spontaneously hypertensive rats after peroral administration by using 1% methyl cellulose as vehicle at 2 mg/kg,Other,6102151.0,
297,188866,3,4,,103171825,3637,Unspecified,,,,,Maximum percentage reduction in mean blood pressure and heart rate in metacorticoid (DOCA) hypertensive rats at a standard oral dose of 5 mg/kg,Other,3361578.0,
298,188867,3,4,,103171825,3637,Unspecified,,,,,Maximum percentage reduction in mean blood pressure and heart rate in metacorticoid (DOCA) hypertensive rats at a standard oral dose of 5 mg/kg,Other,3361579.0,
299,190213,3,4,,103171825,3637,Unspecified,,,,,Antihypertensive activity rating in conscious SHR after 10 hr post dose at 3 mg/kg (po); Range 20-30%,Other,6827558.0,
300,190214,3,3,,103171825,3637,Unspecified,,,,,Antihypertensive activity rating in conscious SHR after 24 h post dose at 3 mg/kg (po); Range 10-20%,Other,6827558.0,
301,191906,3,5,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in DOCA/saline rat dosed at 2 mg/kg, administered perorally expressed as percent rise in heart rate after 2 h",Other,6827559.0,
302,191907,5,3,,103171825,3637,Inactive,,,,,"Antihypertensive activity in DOCA/saline rat dosed at 2 mg/kg, administered perorally expressed as percent rise in heart rate after 6 h; NS is not significant",Other,6827559.0,
303,194404,3,4,,103171825,3637,Unspecified,,,,,The compound was tested for vasodilator activity in ganglion blocked rats. values denote percent change in mean arterial blood pressure 30 minutes after dosing rats at 1 mg/kg intravenously,Other,6102605.0,
304,386623,4,8,,103171825,3637,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
305,408066,3,3,,103171825,3637,Active,,,,,Inhibition of 4-hydroxynonenal-induced carbonyl stress in HMEC1 cells assessed as prevention of increase in carbonylated protein level at 100 uM relative to control,Other,18465848.0,
306,409954,4,9,,103171825,3637,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
307,409956,4,9,,103171825,3637,Inactive,341940629.0,109731.0,,,Inhibition of mouse brain MAOB,Other,18834112.0,
308,425652,7,2,,103171825,3637,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
309,425653,7,2,,103171825,3637,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
310,434959,1,1,,85789545,3637,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
311,461001,3,10,,103171825,3637,Unspecified,12231019.0,1786.0,,,Inhibition of human recombinant DNMT1 expressed in baculovirus-insect cell system at 100 uM by scintillation counting,Other,20006515.0,
312,461002,3,9,,103171825,3637,Unspecified,17375667.0,1789.0,,,Inhibition of human recombinant DNMT3B expressed in baculovirus-insect cell system at 100 uM by scintillation counting,Other,20006515.0,
313,463106,1,2,,90341825,3637,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
314,467618,3,4,,103171825,3637,Unspecified,,,,,Vasodilatory activity in Wistar rat thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction at 10 uM treated after phenylephrine challenge,Other,19589624.0,
315,467619,5,3,,103171825,3637,Unspecified,,,,IC50,Vasodilatory activity in Wistar rat thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction treated after phenylephrine challenge,Confirmatory,19589624.0,
316,485281,1,1,,11111262,3637,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
317,485290,1,1,,11111262,3637,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
318,485295,1,2,,90341825,3637,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
319,485297,1,1,,90341825,3637,Active,4759012.0,9367.0,2.3109,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
320,485298,1,1,,90341825,3637,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
321,485313,1,2,,90341825,3637,Active,255652944.0,4864.0,2.5929,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
322,485342,1,2,,90341825,3637,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
323,485345,1,2,,90341825,3637,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
324,485366,1,2,,90341825,3637,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
325,485368,1,2,,90341825,3637,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
326,486735,3,3,,103171825,3637,Unspecified,,,,,"Antihypertensive activity against methyl prednisolone acetate-indcuced hypertension in normotensive albino rat assessed as reduction in mean arterial pressure at 20 mg/kg, ip after 1 hr",Other,20189270.0,
327,488772,1,1,,90341825,3637,Inconclusive,8659577.0,58819.0,18.8876,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
328,488773,1,2,,90341825,3637,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
329,488816,1,1,,90341825,3637,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
330,488837,1,1,,90341825,3637,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
331,488949,1,2,,90341825,3637,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
332,488953,1,1,,90341825,3637,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
333,488978,1,1,,90341825,3637,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
334,488981,1,1,,90341825,3637,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
335,488982,1,1,,90341825,3637,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
336,488983,1,1,,90341825,3637,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
337,492961,1,1,,11111262,3637,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
338,493106,1,1,,90341825,3637,Active,116283940.0,79915.0,0.8196,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
339,493107,1,1,,90341825,3637,Inconclusive,116283940.0,79915.0,0.3661,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
340,493153,1,1,,90341825,3637,Inactive,,4780.0,1.1582,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
341,493153,1,1,,90341825,3637,Inactive,224028257.0,4780.0,1.1582,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
342,493164,1,2,,90341825,3637,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
343,493164,1,2,,90341825,3637,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
344,493164,1,2,,90341825,3637,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
345,504327,1,1,,11111262,3637,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
346,504327,1,1,,90341825,3637,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
347,504332,1,1,,11111262,3637,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
348,504332,1,1,,90341825,3637,Active,168985070.0,,7.9433,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
349,504536,1,1,,90341825,3637,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
350,504547,1,1,,90341825,3637,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
351,504548,1,2,,90341825,3637,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
352,504749,1,3,,11111262,3637,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
353,504749,1,3,1.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
354,504749,1,3,2.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
355,504749,1,3,3.0,11111262,3637,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
356,504749,1,3,4.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
357,504749,1,3,5.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
358,504749,1,3,6.0,11111262,3637,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
359,504749,1,3,7.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
360,504749,1,3,8.0,11111262,3637,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
361,504749,1,3,9.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
362,504749,1,3,10.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
363,504749,1,3,11.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
364,504749,1,3,12.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
365,504749,1,3,13.0,11111262,3637,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
366,504749,1,3,14.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
367,504749,1,3,15.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
368,504749,1,3,16.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
369,504749,1,3,17.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
370,504749,1,3,18.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
371,504749,1,3,19.0,11111262,3637,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
372,504749,1,3,20.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
373,504749,1,3,21.0,11111262,3637,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
374,504749,1,3,22.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
375,504749,1,3,23.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
376,504749,1,3,24.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
377,504749,1,3,25.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
378,504749,1,3,26.0,11111262,3637,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
379,504749,1,3,27.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
380,504749,1,3,28.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
381,504749,1,3,29.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
382,504749,1,3,30.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
383,504749,1,3,31.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
384,504749,1,3,32.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
385,504749,1,3,33.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
386,504749,1,3,34.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
387,504749,1,3,35.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
388,504749,1,3,36.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
389,504749,1,3,37.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
390,504749,1,3,38.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
391,504749,1,3,39.0,11111262,3637,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
392,504749,1,3,40.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
393,504749,1,3,41.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
394,504749,1,3,42.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
395,504749,1,3,43.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
396,504749,1,3,44.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
397,504749,1,3,45.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
398,504749,1,3,46.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
399,504749,1,3,47.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
400,504749,1,3,48.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
401,504749,1,3,49.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
402,504749,1,3,50.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
403,504749,1,3,51.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
404,504749,1,3,52.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
405,504749,1,3,53.0,11111262,3637,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
406,504749,1,3,54.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
407,504749,1,3,55.0,11111262,3637,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
408,504749,1,3,56.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
409,504749,1,3,57.0,11111262,3637,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
410,504749,1,3,58.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
411,504749,1,3,59.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
412,504749,1,3,60.0,11111262,3637,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
413,504749,1,3,61.0,11111262,3637,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
414,504810,1,2,,90341825,3637,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
415,504812,1,2,,90341825,3637,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
416,504832,1,1,,11111262,3637,Inconclusive,,,2.5575,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
417,504834,1,1,,11111262,3637,Inconclusive,,,9.0743,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
418,504836,1,2,,90341825,3637,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
419,504845,1,1,,90341825,3637,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
420,504847,1,1,,11111262,3637,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
421,504847,1,1,,90341825,3637,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
422,504865,1,1,,11111262,3637,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
423,504865,1,1,,90341825,3637,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
424,540209,4,3,,103171825,3637,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
425,540210,4,3,,103171825,3637,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
426,540211,2,5,,103171825,3637,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
427,540212,4,3,,103171825,3637,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
428,540213,4,3,,103171825,3637,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
429,540256,1,2,,90341825,3637,Inconclusive,,,0.4108,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
430,540276,1,2,,11111261,3637,Inconclusive,420597.0,,18.3489,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
431,540276,1,2,,11111262,3637,Inconclusive,420597.0,,18.3489,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
432,540276,1,2,,50111090,3637,Inconclusive,420597.0,,18.3489,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
433,540276,1,2,,90341825,3637,Inconclusive,420597.0,,18.3489,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
434,568396,2,3,,103171825,3637,Unspecified,,,,,"Antihypertensive activity against methyl prednisolone acetate-induced hypertension in albino rat assessed as reduction in mean arterial pressure at 2.6 mg/kg, ip after 1 hr by tail-cuff method",Other,21211966.0,
435,588211,2,3,,103171825,3637,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
436,588212,2,3,,103171825,3637,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
437,588213,2,3,,103171825,3637,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
438,588220,2,3,,103171825,3637,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
439,588349,1,1,,90341825,3637,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
440,588378,1,1,,90341825,3637,Inactive,171543895.0,6311.0,0.4467,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
441,588453,1,1,,90341825,3637,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
442,588456,1,1,,90341825,3637,Inconclusive,8659577.0,58819.0,18.8876,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
443,588579,1,1,,11111262,3637,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
444,588579,1,1,,90341825,3637,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
445,588795,1,1,,90341825,3637,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
446,602332,1,1,,11111262,3637,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
447,602332,1,1,,90341825,3637,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
448,624030,1,2,,11111262,3637,Active,160794.0,,0.0775,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
449,624031,1,2,,11111262,3637,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
450,624032,1,2,,11111262,3637,Inactive,8393992.0,24660.0,0.0346,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
451,624044,1,2,,11111262,3637,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
452,624101,1,2,,85789545,3637,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
453,624137,1,1,,85789545,3637,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
454,624146,1,1,,90341825,3637,Inconclusive,71051501.0,2744.0,12.5893,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
455,624147,1,1,,90341825,3637,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
456,624148,1,2,,90341825,3637,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
457,624149,1,1,,90341825,3637,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
458,624156,1,1,,85789545,3637,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
459,624170,1,1,,11111262,3637,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
460,624172,1,1,,11111262,3637,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
461,624173,1,3,,11111262,3637,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
462,624260,1,1,,85789545,3637,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
463,624296,1,1,,11111262,3637,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
464,624297,1,1,,11111262,3637,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
465,624455,1,1,,90341825,3637,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
466,625144,5,5,,103171825,3637,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
467,625145,4,7,,103171825,3637,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
468,625146,5,5,,103171825,3637,Active,126397.0,100009114.0,3.6489999999999996,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
469,625147,4,7,,103171825,3637,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
470,625148,4,7,,103171825,3637,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
471,625149,4,7,,103171825,3637,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
472,625150,5,5,,103171825,3637,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
473,625151,4,7,,103171825,3637,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
474,625152,4,7,,103171825,3637,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
475,625153,4,7,,103171825,3637,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
476,625154,4,7,,103171825,3637,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
477,625155,4,7,,103171825,3637,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
478,625156,1,9,,103171825,3637,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
479,625157,6,2,,103171825,3637,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
480,625158,3,4,,103171825,3637,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
481,625159,5,5,,103171825,3637,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
482,625160,1,9,,103171825,3637,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
483,625161,4,7,,103171825,3637,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
484,625162,4,7,,103171825,3637,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
485,625163,4,7,,103171825,3637,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
486,625164,1,6,,103171825,3637,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
487,625165,3,4,,103171825,3637,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
488,625166,3,4,,103171825,3637,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
489,625167,5,5,,103171825,3637,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
490,625168,4,7,,103171825,3637,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
491,625169,1,6,,103171825,3637,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
492,625170,3,4,,103171825,3637,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
493,625171,4,7,,103171825,3637,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
494,625172,4,7,,103171825,3637,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
495,625173,5,5,,103171825,3637,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
496,625174,5,5,,103171825,3637,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
497,625175,5,5,,103171825,3637,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
498,625176,1,9,,103171825,3637,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
499,625177,5,5,,103171825,3637,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
500,625178,5,5,,103171825,3637,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
501,625179,1,9,,103171825,3637,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
502,625180,5,5,,103171825,3637,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
503,625181,5,5,,103171825,3637,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
504,625182,5,5,,103171825,3637,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
505,625183,5,5,,103171825,3637,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
506,625184,5,5,,103171825,3637,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
507,625185,5,5,,103171825,3637,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
508,625186,5,5,,103171825,3637,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
509,625187,5,5,,103171825,3637,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
510,625188,1,9,,103171825,3637,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
511,625189,1,7,,103171825,3637,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
512,625190,4,5,,103171825,3637,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
513,625191,4,7,,103171825,3637,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
514,625192,4,7,,103171825,3637,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
515,625193,5,5,,103171825,3637,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
516,625194,4,7,,103171825,3637,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
517,625195,4,7,,103171825,3637,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
518,625196,5,6,,103171825,3637,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
519,625197,3,4,,103171825,3637,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
520,625198,4,7,,103171825,3637,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
521,625199,4,7,,103171825,3637,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
522,625200,4,7,,103171825,3637,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
523,625201,4,7,,103171825,3637,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
524,625202,4,7,,103171825,3637,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
525,625203,4,7,,103171825,3637,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
526,625204,4,7,,103171825,3637,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
527,625205,4,7,,103171825,3637,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
528,625206,4,7,,103171825,3637,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
529,625207,4,7,,103171825,3637,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
530,625208,5,5,,103171825,3637,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
531,625209,4,7,,103171825,3637,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
532,625210,3,4,,103171825,3637,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
533,625211,1,6,,103171825,3637,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
534,625212,3,4,,103171825,3637,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
535,625213,4,7,,103171825,3637,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
536,625214,1,9,,103171825,3637,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
537,625215,3,4,,103171825,3637,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
538,625216,3,4,,103171825,3637,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
539,625217,4,7,,103171825,3637,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
540,625218,4,7,,103171825,3637,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
541,625219,3,4,,103171825,3637,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
542,625220,4,7,,103171825,3637,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
543,625221,4,7,,103171825,3637,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
544,625222,4,7,,103171825,3637,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
545,625223,4,7,,103171825,3637,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
546,625224,3,4,,103171825,3637,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
547,625225,3,4,,103171825,3637,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
548,625226,4,7,,103171825,3637,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
549,625227,4,7,,103171825,3637,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
550,625228,4,7,,103171825,3637,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
551,625229,5,5,,103171825,3637,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
552,625230,1,6,,103171825,3637,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
553,625231,4,7,,103171825,3637,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
554,625232,1,9,,103171825,3637,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
555,625233,4,7,,103171825,3637,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
556,625234,3,4,,103171825,3637,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
557,625235,4,7,,103171825,3637,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
558,625236,5,5,,103171825,3637,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
559,625237,4,7,,103171825,3637,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
560,625238,4,7,,103171825,3637,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
561,625239,4,7,,103171825,3637,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
562,625240,1,9,,103171825,3637,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
563,625241,4,7,,103171825,3637,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
564,625242,4,7,,103171825,3637,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
565,625243,5,5,,103171825,3637,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
566,625244,5,5,,103171825,3637,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
567,625245,5,5,,103171825,3637,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
568,625246,1,9,,103171825,3637,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
569,625247,5,5,,103171825,3637,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
570,625248,5,5,,103171825,3637,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
571,625249,5,5,,103171825,3637,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
572,625250,5,5,,103171825,3637,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
573,625251,5,5,,103171825,3637,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
574,625252,4,7,,103171825,3637,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
575,625253,4,7,,103171825,3637,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
576,625254,4,7,,103171825,3637,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
577,625255,4,7,,103171825,3637,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
578,625256,4,7,,103171825,3637,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
579,625257,4,7,,103171825,3637,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
580,625258,4,7,,103171825,3637,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
581,625259,4,7,,103171825,3637,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
582,625260,3,4,,103171825,3637,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
583,625261,3,4,,103171825,3637,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
584,625262,3,4,,103171825,3637,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
585,625263,4,7,,103171825,3637,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
586,625264,3,4,,103171825,3637,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
587,625265,1,6,,103171825,3637,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
588,625266,3,4,,103171825,3637,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
589,625267,3,4,,103171825,3637,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
590,625268,4,2,,103171825,3637,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
591,625268,4,2,,103171825,3637,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
592,625268,4,2,,103171825,3637,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
593,625268,4,2,,103171825,3637,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
594,625269,4,7,,103171825,3637,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
595,625270,4,7,,103171825,3637,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
596,625271,5,5,,103171825,3637,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
597,625272,3,4,,103171825,3637,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
598,625273,4,6,,103171825,3637,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
599,625274,1,6,,103171825,3637,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
600,625275,3,4,,103171825,3637,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
601,625279,1,3,,103171825,3637,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
602,625280,1,3,,103171825,3637,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
603,625281,1,3,,103171825,3637,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
604,625282,1,3,,103171825,3637,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
605,625283,1,3,,103171825,3637,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
606,625284,1,3,,103171825,3637,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
607,625285,1,3,,103171825,3637,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
608,625286,1,3,,103171825,3637,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
609,625287,1,3,,103171825,3637,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
610,625288,1,3,,103171825,3637,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
611,625289,1,3,,103171825,3637,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
612,625290,1,3,,103171825,3637,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
613,625291,1,3,,103171825,3637,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
614,625292,1,3,,103171825,3637,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
615,651548,1,1,,85789545,3637,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
616,651635,1,3,,90341825,3637,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
617,652106,1,1,,90341825,3637,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
618,678712,1,8,,103171825,3637,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
619,678713,1,8,,103171825,3637,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
620,678714,1,8,,103171825,3637,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
621,678715,1,8,,103171825,3637,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
622,678716,1,8,,103171825,3637,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
623,678717,1,8,,103171825,3637,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
624,678719,1,5,,103171825,3637,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
625,678722,1,5,,103171825,3637,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
626,720538,1,2,,90341825,3637,Inactive,220983390.0,410.0,26.8545,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
627,720559,1,2,,90341825,3637,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
628,720572,1,2,,90341825,3637,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
629,720573,1,2,,90341825,3637,Inconclusive,3063388.0,5071.0,0.4109,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
630,743205,1,1,,90341825,3637,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
631,743205,1,1,,90341825,3637,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
632,743206,1,1,,90341825,3637,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
633,743206,1,1,,90341825,3637,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
634,743207,1,1,,90341825,3637,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
635,743207,1,1,,90341825,3637,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
636,743244,1,1,,90341825,3637,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
637,743344,1,1,,174006923,3637,Inactive,,,11.8754,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
638,743345,1,1,,174006923,3637,Inactive,,,0.0017,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
639,743346,1,1,,174006923,3637,Inactive,,,5.9518,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
640,743347,1,1,,174006923,3637,Inactive,,,23.6945,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
641,940690,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020318,Other,,
642,940691,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020318,Other,,
643,941321,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020318,Other,,
644,941322,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020318,Other,,
645,941323,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020318,Other,,
646,941324,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020318,Other,,
647,941325,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020318,Other,,
648,941326,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020318",Other,,
649,941327,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020318,Other,,
650,941328,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020318,Other,,
651,941329,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020318,Other,,
652,941330,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020318,Other,,
653,941331,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020318,Other,,
654,941332,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020318,Other,,
655,941333,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020318,Other,,
656,941334,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020318,Other,,
657,941335,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020318,Other,,
658,941336,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020318,Other,,
659,941337,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020318,Other,,
660,947900,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020318,Other,,
661,947901,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020318,Other,,
662,947902,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020318,Other,,
663,947903,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020318,Other,,
664,947904,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020318,Other,,
665,947905,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020318,Other,,
666,947906,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020318",Other,,
667,947907,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020318,Other,,
668,947908,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020318,Other,,
669,947909,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020318,Other,,
670,948056,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020318,Other,,
671,948057,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020318,Other,,
672,948058,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020318,Other,,
673,948059,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020318,Other,,
674,948060,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020318,Other,,
675,948061,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020318,Other,,
676,948062,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020318,Other,,
677,948063,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020318,Other,,
678,948064,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020318,Other,,
679,949746,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020318,Other,,
680,949747,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020318,Other,,
681,949748,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020318,Other,,
682,949749,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020318,Other,,
683,949750,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020318,Other,,
684,949751,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020318,Other,,
685,949752,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020318,Other,,
686,949753,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020318,Other,,
687,949754,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020318,Other,,
688,949755,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020318,Other,,
689,949756,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020318,Other,,
690,949757,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020318,Other,,
691,949758,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020318,Other,,
692,949759,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020318,Other,,
693,949760,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020318,Other,,
694,951782,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020318,Other,,
695,951783,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020318,Other,,
696,951784,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020318,Other,,
697,951785,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020318,Other,,
698,963894,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020318,Other,,
699,963895,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020318,Other,,
700,963896,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020318,Other,,
701,963897,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020318,Other,,
702,963898,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020318,Other,,
703,963899,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020318,Other,,
704,963900,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020318,Other,,
705,963901,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020318,Other,,
706,963902,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020318,Other,,
707,963903,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020318,Other,,
708,963904,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020318,Other,,
709,963905,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020318,Other,,
710,963906,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020318,Other,,
711,963907,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020318,Other,,
712,963908,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020318,Other,,
713,963909,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020318,Other,,
714,963910,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020318,Other,,
715,963911,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020318,Other,,
716,963912,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020318,Other,,
717,998758,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020318",Other,,
718,998759,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020318",Other,,
719,998760,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020318",Other,,
720,998761,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020318",Other,,
721,998762,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020318",Other,,
722,1001203,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020318,Other,,
723,1001204,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020318",Other,,
724,1001205,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020318,Other,,
725,1001206,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020318",Other,,
726,1001207,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020318",Other,,
727,1001208,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020318",Other,,
728,1001209,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020318",Other,,
729,1001210,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020318",Other,,
730,1001211,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020318",Other,,
731,1001212,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020318",Other,,
732,1001213,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020318",Other,,
733,1001214,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020318",Other,,
734,1001215,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
735,1001216,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020318",Other,,
736,1001217,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020318",Other,,
737,1001218,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020318",Other,,
738,1001219,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020318",Other,,
739,1001220,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020318",Other,,
740,1001221,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020318",Other,,
741,1001222,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020318",Other,,
742,1001223,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020318",Other,,
743,1001224,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020318",Other,,
744,1001225,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020318",Other,,
745,1001226,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020318,Other,,
746,1001227,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020318,Other,,
747,1001228,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020318",Other,,
748,1001229,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020318",Other,,
749,1001230,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
750,1001231,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020318",Other,,
751,1001232,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020318,Other,,
752,1001233,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
753,1001234,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020318",Other,,
754,1001235,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020318",Other,,
755,1001236,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020318",Other,,
756,1001237,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020318,Other,,
757,1001820,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
758,1001821,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020318",Other,,
759,1001822,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020318",Other,,
760,1001823,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020318",Other,,
761,1001824,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020318",Other,,
762,1002916,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020318",Other,,
763,1002917,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020318",Other,,
764,1002918,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020318",Other,,
765,1002919,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020318,Other,,
766,1002920,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020318",Other,,
767,1002921,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020318",Other,,
768,1002922,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020318",Other,,
769,1002923,1,3,,103171825,3637,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020318,Other,,
770,1002924,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020318",Other,,
771,1002925,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020318",Other,,
772,1002926,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020318",Other,,
773,1002927,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020318",Other,,
774,1002928,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020318",Other,,
775,1002929,1,3,,103171825,3637,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020318",Other,,
776,1079931,1,1,,103171825,3637,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
777,1079932,1,1,,103171825,3637,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
778,1079933,1,1,,103171825,3637,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
779,1079934,1,1,,103171825,3637,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
780,1079935,1,1,,103171825,3637,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
781,1079936,1,1,,103171825,3637,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
782,1079937,1,1,,103171825,3637,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
783,1079938,1,1,,103171825,3637,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
784,1079939,1,1,,103171825,3637,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
785,1079940,1,1,,103171825,3637,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
786,1079941,1,1,,103171825,3637,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
787,1079942,1,1,,103171825,3637,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
788,1079943,1,1,,103171825,3637,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
789,1079944,1,1,,103171825,3637,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
790,1079945,1,1,,103171825,3637,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
791,1079946,1,1,,103171825,3637,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
792,1079947,1,1,,103171825,3637,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
793,1079948,1,1,,103171825,3637,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
794,1079949,1,1,,103171825,3637,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
795,1130344,1,1,,103171825,3637,Unspecified,,,,,Toxicity in ip dosed CF-1 mouse after 48 hrs,Other,458822.0,
796,1130345,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 30 mg/kg, po after 4 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
797,1130346,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 30 mg/kg, po after 24 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
798,1130347,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 30 mg/kg, po followed by second dosing at 24 hrs measured after 28 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
799,1130348,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 30 mg/kg, po followed by second dosing at 24 hrs measured after 48 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
800,1130349,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 10 mg/kg, po after 4 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
801,1130350,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 10 mg/kg, po after 24 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
802,1130351,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 10 mg/kg, po followed by second dosing at 24 hrs measured after 28 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
803,1130352,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 10 mg/kg, po followed by second dosing at 24 hrs measured after 48 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
804,1130353,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 3 mg/kg, po after 4 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
805,1130354,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 3 mg/kg, po after 24 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
806,1130355,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 3 mg/kg, po followed by second dosing at 24 hrs measured after 28 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
807,1130356,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 3 mg/kg, po followed by second dosing at 24 hrs measured after 48 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
808,1130361,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 30 mg/kg, po after 4 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
809,1130362,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 30 mg/kg, po after 24 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
810,1130363,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 30 mg/kg, po followed by second dosing at 24 hrs measured after 28 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
811,1130364,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 30 mg/kg, po followed by second dosing at 24 hrs measured after 48 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
812,1130365,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 10 mg/kg, po after 4 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
813,1130366,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 10 mg/kg, po after 24 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
814,1130367,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 10 mg/kg, po followed by second dosing at 24 hrs measured after 28 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
815,1130368,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 10 mg/kg, po followed by second dosing at 24 hrs measured after 48 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
816,1130369,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 3 mg/kg, po after 4 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
817,1130370,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 3 mg/kg, po after 24 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
818,1130371,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 3 mg/kg, po followed by second dosing at 24 hrs measured after 28 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
819,1130372,1,2,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 3 mg/kg, po followed by second dosing at 24 hrs measured after 48 hrs by tail cuff method relative to vehicle-treated control",Other,458822.0,
820,1130373,1,1,,103171825,3637,Unspecified,,,,,Drug excretion in human assessed as para-hydroxylated metabolite,Other,458822.0,
821,1135146,1,2,,103171825,3637,Inactive,,,,,Antagonist activity at guinea pig atrial beta adrenergic receptor assessed as isometric contractions at 5 x 10'-5 M by force displacement transducer,Other,15112.0,
822,1135155,1,2,,103171825,3637,Unspecified,,,,,"Hypotensive activity at guinea pig assessed as decrease in blood pressure at 5 mg/kg, po after 1 hr (Rvb = 112 +/- 2.6 to 122 +/- 2.7 mmHg)",Other,15112.0,
823,1135156,1,2,,103171825,3637,Unspecified,,,,,"Hypotensive activity at guinea pig assessed as decrease in blood pressure at 5 mg/kg, po after 2 hrs (Rvb = 112 +/- 2.6 to 122 +/- 2.7 mmHg)",Other,15112.0,
824,1135157,1,2,,103171825,3637,Unspecified,,,,,"Hypotensive activity at guinea pig assessed as decrease in blood pressure at 5 mg/kg, po after 3 hrs (Rvb = 112 +/- 2.6 to 122 +/- 2.7 mmHg)",Other,15112.0,
825,1135544,1,1,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as maximum fall in mean arterial pressure at 1 mg/kg, po",Other,19628.0,
826,1135545,1,1,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as maximum fall in mean arterial pressure at 2 mg/kg, po",Other,19628.0,
827,1135552,1,1,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as maximum fall in mean arterial pressure at 0.5 mg/kg, po",Other,19628.0,
828,1135553,1,1,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as duration of effect at 1 mg/kg, po",Other,19628.0,
829,1135554,1,1,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as duration of effect at 2 mg/kg, po",Other,19628.0,
830,1135561,1,1,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as duration of effect at 0.5 mg/kg, po",Other,19628.0,
831,1135564,1,1,,103171825,3637,Unspecified,,,,,Peripheral vasodilating activity in anesthetized trachea-cannulated mongrel dog assessed as increase in iliac blood flow at 1600 ug administered intraarterially in presence of isoproterenol,Other,19628.0,
832,1135569,1,1,,103171825,3637,Unspecified,,,,,Peripheral vasodilating activity in anesthetized trachea-cannulated mongrel dog assessed as increase in iliac blood flow at 400 ug administered intraarterially in presence of isoproterenol,Other,19628.0,
833,1135570,1,1,,103171825,3637,Unspecified,,,,,Peripheral vasodilating activity in anesthetized trachea-cannulated mongrel dog assessed as increase in iliac blood flow at 3200 ug administered intraarterially in presence of isoproterenol,Other,19628.0,
834,1135577,1,1,,103171825,3637,Inconclusive,,,,,Blockade of isoprolerenol-induced hypotension in iv dosed anesthetized trachea-cannulated mongrel dog assessed as mean arterial pressure,Other,19628.0,
835,1135578,1,2,,103171825,3637,Inconclusive,,,,,Blockade of isoprolerenol-induced tachycardia in iv dosed anesthetized trachea-cannulated mongrel dog assessed as heart rate,Other,19628.0,
836,1136795,1,1,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as maximum fall in mean arterial pressure at 0.5 mg/kg, po",Other,37337.0,
837,1136796,1,1,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as maximum fall in mean arterial pressure at 1 mg/kg, po",Other,37337.0,
838,1136797,1,1,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as maximum fall in mean arterial pressure at 2 mg/kg, po",Other,37337.0,
839,1136801,1,1,,103171825,3637,Unspecified,,,,,"Peripheral vasodilating activity in mongrel dog assessed as increase in iliac blood flow at 1600 ug, ia",Other,37337.0,
840,1136803,1,1,,103171825,3637,Unspecified,,,,,"Peripheral vasodilating activity in mongrel dog assessed as increase in iliac blood flow at 400 ug, ia",Other,37337.0,
841,1136804,1,1,,103171825,3637,Unspecified,,,,,"Peripheral vasodilating activity in mongrel dog assessed as increase in iliac blood flow at 3200 ug, ia",Other,37337.0,
842,1136814,1,1,,103171825,3637,Unspecified,,,,,"Peripheral vasodilating activity in mongrel dog at 100 ug/kg, iv assessed as increase in iliac blood flow after 30 mins in presence of propranolol relative to control",Other,37337.0,
843,1136815,1,1,,103171825,3637,Unspecified,,,,,"Peripheral vasodilating activity in mongrel dog at 100 ug/kg, iv assessed as increase in iliac blood flow after 30 mins relative to control",Other,37337.0,
844,1137369,1,1,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximal fall in mean arterial pressure at 0.5 mg/kg, po",Other,42797.0,
845,1137370,1,1,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximal fall in mean arterial pressure at 1 mg/kg, po",Other,42797.0,
846,1137371,1,1,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximal fall in mean arterial pressure at 2 mg/kg, po",Other,42797.0,
847,1137380,1,1,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as duration of action at 0.5 mg/kg, po",Other,42797.0,
848,1137381,1,1,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as duration of action at 1 mg/kg, po",Other,42797.0,
849,1137382,1,1,,103171825,3637,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as duration of action at 2 mg/kg, po",Other,42797.0,
850,1137389,1,1,,103171825,3637,Unspecified,,,,,"Vasodilatory activity in anesthetized dog assessed as increase in iliac blood flow at 400 mg, ia",Other,42797.0,
851,1137390,1,1,,103171825,3637,Unspecified,,,,,"Vasodilatory activity in anesthetized dog assessed as increase in iliac blood flow at 1600 mg, ia",Other,42797.0,
852,1137391,1,1,,103171825,3637,Unspecified,,,,,"Vasodilatory activity in anesthetized dog assessed as increase in iliac blood flow at 3200 mg, ia",Other,42797.0,
853,1148551,1,1,,103171825,3637,Unspecified,,,,,Toxicity in po dosed Sprague-Dawley rat assessed as mortality after 7 days,Other,691003.0,
854,1148552,1,2,,103171825,3637,Unspecified,,,,,"Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximum change in mean blood pressure at 2.5 mg/kg, po relative to control",Other,691003.0,
855,1148560,1,2,,103171825,3637,Unspecified,,,,,"Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximum change in mean blood pressure at 1 mg/kg, po relative to control",Other,691003.0,
856,1148561,1,1,,103171825,3637,Unspecified,,,,,"Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as time required for persistence of hypotensive effect at 2.5 mg/kg, po",Other,691003.0,
857,1148569,1,1,,103171825,3637,Unspecified,,,,,"Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as time required for persistence of hypotensive effect at 1 mg/kg, po",Other,691003.0,
858,1148576,1,2,,103171825,3637,Unspecified,,,,,"Hypotensive activity in conscious renal hypertensive dog assessed as maximum change in mean blood pressure at 0.5 mg/kg, po measured for 8 hrs relative to control",Other,691003.0,
859,1148578,1,2,,103171825,3637,Unspecified,,,,,"Hypotensive activity in conscious renal hypertensive dog assessed as maximum change in mean blood pressure at 1 mg/kg, po measured for 8 hrs relative to control",Other,691003.0,
860,1148585,1,1,,103171825,3637,Unspecified,,,,,"Hypotensive activity in conscious renal hypertensive dog assessed as time required for persistence of hypotensive effect at 0.5 mg/kg, po measured for 8 hrs",Other,691003.0,
861,1148587,1,1,,103171825,3637,Unspecified,,,,,"Hypotensive activity in conscious renal hypertensive dog assessed as time required for persistence of hypotensive effect at 1 mg/kg, po measured for 8 hrs",Other,691003.0,
862,1148591,1,2,,103171825,3637,Active,,,,,"Vasodilatory activity in conscious normotensive dog assessed as change in blood pressure at 0.25 mg/kg, po",Other,691003.0,
863,1148592,1,2,,103171825,3637,Active,,,,,"Vasodilatory activity in conscious normotensive dog assessed as change in blood pressure at 0.1 mg/kg, po",Other,691003.0,
864,1148593,1,2,,103171825,3637,Active,,,,,"Vasodilatory activity in conscious normotensive dog assessed as change in blood pressure at 0.5 mg/kg, po",Other,691003.0,
865,1148594,1,2,,103171825,3637,Active,,,,,"Vasodilatory activity in conscious normotensive dog assessed as change in blood pressure at 5 mg/kg, po",Other,691003.0,
866,1148595,1,2,,103171825,3637,Active,,,,,"Vasodilatory activity in conscious normotensive dog assessed as change in heart rate at 0.25 mg/kg, po",Other,691003.0,
867,1148596,1,2,,103171825,3637,Active,,,,,"Vasodilatory activity in conscious normotensive dog assessed as change in heart rate at 0.1 mg/kg, po",Other,691003.0,
868,1148597,1,2,,103171825,3637,Active,,,,,"Vasodilatory activity in conscious normotensive dog assessed as change in heart rate at 0.5 mg/kg, po",Other,691003.0,
869,1148598,1,2,,103171825,3637,Active,,,,,"Vasodilatory activity in conscious normotensive dog assessed as change in heart rate at 5 mg/kg, po",Other,691003.0,
870,1148599,1,1,,103171825,3637,Active,,,,,"Vasodilatory activity in conscious normotensive dog assessed as cardiac output at 0.25 mg/kg, po by thermodilution method",Other,691003.0,
871,1148600,1,1,,103171825,3637,Active,,,,,"Vasodilatory activity in conscious normotensive dog assessed as cardiac output at 0.1 mg/kg, po by thermodilution method",Other,691003.0,
872,1148601,1,1,,103171825,3637,Active,,,,,"Vasodilatory activity in conscious normotensive dog assessed as cardiac output at 0.5 mg/kg, po by thermodilution method",Other,691003.0,
873,1148602,1,1,,103171825,3637,Active,,,,,"Vasodilatory activity in conscious normotensive dog assessed as cardiac output at 5 mg/kg, po by thermodilution method",Other,691003.0,
874,1148603,1,1,,103171825,3637,Active,,,,,"Vasodilatory activity in conscious normotensive dog assessed as total peripheral resistance at 0.25 mg/kg, po",Other,691003.0,
875,1148604,1,1,,103171825,3637,Active,,,,,"Vasodilatory activity in conscious normotensive dog assessed as total peripheral resistance at 0.1 mg/kg, po",Other,691003.0,
876,1148605,1,1,,103171825,3637,Active,,,,,"Vasodilatory activity in conscious normotensive dog assessed as total peripheral resistance at 0.5 mg/kg, po",Other,691003.0,
877,1148606,1,1,,103171825,3637,Active,,,,,"Vasodilatory activity in conscious normotensive dog assessed as total peripheral resistance at 5 mg/kg, po",Other,691003.0,
878,1149605,1,2,,103171825,3637,Unspecified,,,,,Antihypertensive activity in po dosed renal hypertensive rat assessed as dose required to produce lowering of blood pressure to <= 130 mm after 2 to 24 hrs by photoelectric tensometric analysis,Other,845877.0,
879,1155746,3,2,,103171825,3637,Unspecified,,,1180.0,EC50,Vasorelaxant activity in Wistar rat endothelium-intact thoracic aortic rings assessed as inhibition of phenylephrine-induced contraction,Confirmatory,24929291.0,
880,1155747,3,2,,103171825,3637,Unspecified,,,1320.0,EC50,Vasorelaxant activity in Wistar rat endothelium-denuded thoracic aortic rings assessed as inhibition of phenylephrine-induced contraction,Confirmatory,24929291.0,
881,1159580,2,1,,268734571,3637,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
882,1159580,2,1,,273002837,3637,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
883,1159607,2,1,,312995643,3637,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
884,1210795,1,2,,103171825,3637,Unspecified,215273968.0,316.0,,,Inhibition of human liver cytosolic aldehyde oxidase using DACA as substrate by LC-MS/MS analysis relative to control,Other,22996261.0,
885,1215658,1,2,,103171825,3637,Unspecified,117144.0,1544.0,,,Inhibition of CYP1A2 in human liver microsomes assessed as residual activity using phenacetin as substrate at 25 uM relative to control,Other,22522748.0,
886,1215659,1,2,,103171825,3637,Unspecified,117144.0,1544.0,,,Inhibition of CYP1A2 in human liver microsomes assessed as residual activity using phenacetin as substrate at 50 uM relative to control,Other,22522748.0,
887,1215660,1,2,,103171825,3637,Unspecified,117225.0,1558.0,,,Inhibition of CYP2C8 in human liver microsomes assessed as residual activity using paclitaxel as substrate at 25 uM relative to control,Other,22522748.0,
888,1215661,1,2,,103171825,3637,Unspecified,117225.0,1558.0,,,Inhibition of CYP2C8 in human liver microsomes assessed as residual activity using paclitaxel as substrate at 50 uM relative to control,Other,22522748.0,
889,1215662,1,2,,103171825,3637,Unspecified,6686268.0,1559.0,,,Inhibition of CYP2C9 in human liver microsomes assessed as residual activity using diclofenac as substrate at 25 uM relative to control,Other,22522748.0,
890,1215663,1,2,,103171825,3637,Unspecified,6686268.0,1559.0,,,Inhibition of CYP2C9 in human liver microsomes assessed as residual activity using diclofenac as substrate at 50 uM relative to control,Other,22522748.0,
891,1215664,1,2,,103171825,3637,Unspecified,60416369.0,1557.0,,,Inhibition of CYP2C19 in human liver microsomes assessed as residual activity using S-mephenytoin as substrate at 25 uM relative to control,Other,22522748.0,
892,1215665,1,2,,103171825,3637,Unspecified,60416369.0,1557.0,,,Inhibition of CYP2C19 in human liver microsomes assessed as residual activity using S-mephenytoin as substrate at 50 uM relative to control,Other,22522748.0,
893,1215666,1,2,,103171825,3637,Unspecified,84028191.0,1565.0,,,Inhibition of CYP2D6 in human liver microsomes assessed as residual activity using dextromethorphan as substrate at 25 uM relative to control,Other,22522748.0,
894,1215667,1,2,,103171825,3637,Unspecified,84028191.0,1565.0,,,Inhibition of CYP2D6 in human liver microsomes assessed as residual activity using dextromethorphan as substrate at 50 uM relative to control,Other,22522748.0,
895,1215668,1,2,,103171825,3637,Unspecified,,,,,Inhibition of CYP3A in human liver microsomes assessed as residual activity using midazolam as substrate at 25 uM relative to control,Other,22522748.0,
896,1215669,1,2,,103171825,3637,Unspecified,,,,,Inhibition of CYP3A in human liver microsomes assessed as residual activity using midazolam as substrate at 50 uM relative to control,Other,22522748.0,
897,1224824,1,1,,174006923,3637,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
898,1224825,1,1,,174006923,3637,Inactive,,,0.001,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
899,1224857,2,1,,174006923,3637,Inconclusive,,,18.6548,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
900,1224859,2,1,,90341825,3637,Inconclusive,,,35.4813,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
901,1224859,2,1,,174006923,3637,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
902,1224863,1,1,,176485051,3637,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
903,1224863,1,1,,316919378,3637,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
904,1259252,1,1,,174006923,3637,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
905,1259253,1,1,,174006923,3637,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
906,1259255,1,1,,174006923,3637,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
907,1259256,1,1,,174006923,3637,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
908,1259407,1,1,,363903335,3637,Inactive,,,,,CCRIS mutagenicity studies,Other,,
909,1259423,1,2,,354792724,3637,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
910,1259423,1,2,,354891893,3637,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
911,1259423,1,2,,354921375,3637,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
912,1259423,1,2,,354961466,3637,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
